Skip to main content
HCA HealthcareRevenue

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc.

What happened

HCA Healthcare, Inc. reported that an unfavorable shift in its payer mix impacted revenue by approximately $400 million in the second quarter of 2026.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc.("HCA" or the "Company") (NYSE: HCA ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter. On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the...

Keep reading with a free account

The rest of this article, and every signal for HCA Healthcare, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$400M

More revenue signals at other companies

The full record

From the Signal API record

Numbers

Amount named in the story
$400M

Extraction

Confidence
90%
Detected
Jul 30, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for HCA Healthcare and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at HCA Healthcare this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/690db6dc-ee67-11c2-8ae9-52819660e952 returns this record as JSON. POST /v1/companies/enrich returns every signal for hcahealthcare.com.

{
  "signal_id": "690db6dc-ee67-11c2-8ae9-52819660e952",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-07-30T14:00:00+00:00",
  "company": {
    "name": "HCA Healthcare",
    "domain": "hcahealthcare.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-hca-healthcare-inc---hca-302838731.html",
    "title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc. - HCA",
    "excerpt": "NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc.(\"HCA\" or the \"Company\") (NYSE: HCA ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter. On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the...",
    "summary": "HCA Healthcare, Inc. reported that an unfavorable shift in its payer mix impacted revenue by approximately $400 million in the second quarter of 2026.",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS651528/Pomerantz-V3-Logo.jpg?id=OA2803321&p=facebook",
    "confidence": 0.9,
    "published_at": "2026-07-30T14:00:00Z",
    "article_sentence": "Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter.",
    "amount_normalized": 400000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.